Overview

A Study on the Safety and Tolerability of RGL-193 in Patients With Advanced Parkinson's Disease

Status:
Recruiting
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
A safety study in patients with Parkinson's disease.
Phase:
Early Phase 1
Details
Lead Sponsor:
Second Affiliated Hospital of Soochow University
Collaborator:
Shanghai Regenelead Therapies Co., Ltd.